Developing Prognostic Models for Diffuse Large B-cell Lymphoma

Abstract

Diffuse large B-cell lymphoma (DLBCL) is among the most common lymphomas worldwide, with variable outcome following combined chemotherapy and immunotherapy. For this reason, DLBCL has served as a prototype among lymphomas for developing gene predictors of outcome and therapy response. In this chapter, we review the use of gene expression profiling to discover and validate the outcome predictors in DLBCL. The pathway from marker discovery to routine implementation is discussed, with considerations on use of quantitative transcript profiling by real-time PCR as compared to microarray or immunohistochemistry to look at protein levels.